202 related articles for article (PubMed ID: 29392613)
1. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Sugimoto M; Farnell MB; Nagorney DM; Kendrick ML; Truty MJ; Smoot RL; Chari ST; Moynagh MR; Petersen GM; Carter RE; Takahashi N
J Gastrointest Surg; 2018 May; 22(5):831-839. PubMed ID: 29392613
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
3. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.
Cloyd JM; Nogueras-González GM; Prakash LR; Petzel MQB; Parker NH; Ngo-Huang AT; Fogelman D; Denbo JW; Garg N; Kim MP; Lee JE; Tzeng CD; Fleming JB; Katz MHG
J Gastrointest Surg; 2018 Apr; 22(4):703-712. PubMed ID: 29230694
[TBL] [Abstract][Full Text] [Related]
4. Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer.
Nakano O; Kawai H; Kobayashi T; Kohisa J; Ikarashi S; Hayashi K; Yokoyama J; Terai S
Cancer Med; 2021 Jul; 10(13):4291-4301. PubMed ID: 33993635
[TBL] [Abstract][Full Text] [Related]
5. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
6. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer.
van Dijk DP; Bakens MJ; Coolsen MM; Rensen SS; van Dam RM; Bours MJ; Weijenberg MP; Dejong CH; Olde Damink SW
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):317-326. PubMed ID: 27897432
[TBL] [Abstract][Full Text] [Related]
7. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
Nakamura T; Asano T; Okamura K; Tsuchikawa T; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Shichinohe T; Hirano S
J Gastrointest Surg; 2019 May; 23(5):990-996. PubMed ID: 30242645
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy.
Rom H; Tamir S; Van Vugt JLA; Berger Y; Perl G; Morgenstern S; Tovar A; Brenner B; Benchimol D; Kashtan H; Sadot E
Ann Surg Oncol; 2022 Mar; 29(3):1553-1563. PubMed ID: 34716836
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
10. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.
Kaiser J; Hinz U; Mayer P; Hank T; Niesen W; Hackert T; Gaida MM; Büchler MW; Strobel O
Eur J Surg Oncol; 2021 Jul; 47(7):1734-1741. PubMed ID: 33622577
[TBL] [Abstract][Full Text] [Related]
16. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers.
Chakedis J; Spolverato G; Beal EW; Woelfel I; Bagante F; Merath K; Sun SH; Chafitz A; Galo J; Dillhoff M; Cloyd J; Pawlik TM
J Gastrointest Surg; 2018 Oct; 22(10):1697-1708. PubMed ID: 29855867
[TBL] [Abstract][Full Text] [Related]
18. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
20. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
Xu B; Ding WX; Jin DY; Wang DS; Lou WH
World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
